Prognostic value of baseline and posttreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in head and neck squamous cell carcinoma receiving chemoradiotherapy Prognostic value of NLR in head and neck cancer

Main Article Content

Gülhan Güler Avcı
Ipek Pınar Aral

Abstract

Objective: The aim of this study was to evaluate the prognostic value of baseline and posttreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in head and neck squamous cell carcinoma (HNSCC) receiving chemoradiotherapy (CRT).


Material and methods: Ninety-two HNSCC patients who received adjuvant or primary radiotherapy (RT) between September 2014 and December 2019 were assessed retrospectively. Surgery was performed on 24 (26.1%) patients. Eight patients (8.7%) received induction chemotherapy (CT), 63 patients (68.5%) concomitant CT and 17 (19.5%) patients received adjuvant CT.


Results: The median follow-up time was 19 months (range 1-61 months). The median overall survival (OS) and progression-free survival (PFS) were 16 and 13 months, respectively. High baseline NLR level was found to be significantly associated with advanced T stage. Survival was significantly poor if baseline NLR cut-off was above 2.7. No significant correlation was revealed between post-RT NLR, baseline PLR and post-RT PLR and OS. Advanced T stage, presence of metastasis and high post-RT PLR were found to be significant factors that decrease PFS.


Conclusion: High baseline NLR level in HNSCC receiving CRT/RT was strongly associated with advanced T stage and poor prognosis. However, well designed, larger studies with longer follow-up are warranted.

Downloads

Download data is not yet available.

Article Details

How to Cite
Avcı, G. G. ., & Aral, I. P. (2020). Prognostic value of baseline and posttreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in head and neck squamous cell carcinoma receiving chemoradiotherapy: Prognostic value of NLR in head and neck cancer . Medical Science and Discovery, 7(9), 635–641. https://doi.org/10.36472/msd.v7i9.414
Section
Research Article
Received 2020-08-19
Accepted 2020-09-14
Published 2020-09-25

References

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.

Forastiere A, Koch W, Trotti A, Sidransky D. Head and Neck Cancer. N Engl J Med. 2001;345:1890-900.

Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-55.

Braakhuis BJ, Leemans CR, Visser O. Incidence and survival trends of head and neck squamous cell carcinoma in The Netherlands between 1989 and 2011. Oral Oncol. 2014;50:670-5.

Fuller CD, Wang SJ, Thomas CR Jr, Hoffman HT, Weber RS, Rosenthal DI. Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998. Cancer. 2007;109:1331-43.

Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164:1233-47.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.

Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87:504-8.

Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121:2373-80.

Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19:2.

Yodying H, Matsuda A, Miyashita M, Matsumoto S, Sakurazawa N, Yamada M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:646-54.

Zhang J, Zhang HY, Li J, Shao XY, Zhang CX. The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and metaanalysis. Oncotarget. 2017;8:68837-46.

Yuan C, Li N, Mao X, Liu Z, Ou W, Wang SY. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: results from a large cohort. Thorac Cancer. 2017;8:350-8.

Rassouli A, Saliba J, Castano R, Hier M, Zeitouni AG. Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma. Head Neck. 2015 ;37:103-10.

Selzer E, Grah A, Heiduschka G, Kornek G, Thurnher D. Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems. Strahlenther Onkol. 2015;191:486-94.

Haddad CR, Guo L, Clarke S, Guminski A, Back M, Eade T. Neutrophil-to-lymphocyte ratio in head and neck cancer. J Med Imaging Radiat Oncol. 2015;59:514-9.

Mirghani H, Amen F, Tao Y, Deutsch E, Levy A. Increased radiosensitivity of HPV-positive head and neck cancers: molecular basis and therapeutic perspectives, Cancer Treat. Rev. 2015;41:844–52.

Andersen AS, Koldjaer Solling AS, Ovesen T, Rusan M. The interplay between HPV and host immunity in head and neck squamous cell carcinoma. Int. J. Cancer 2014;134:2755–63.

Malik A, Mishra A, Mair M, Chakrabarti S, Garg A, Singhvi H, et al. Role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in oral cavity cancers. Indian journal of Medical and Paediatric Oncology 2019;40:94-100.

Xu C, Yuan J, Du W, Wu J, Fang Q, Zhang X, et al. Significance of the Neutrophil-to-Lymphocyte Ratio in p16-Negative Squamous Cell Carcinoma of Unknown Primary in Head and Neck. Front Oncol. 2020;10:39.

Lai HL, Tang Y, Chien CY, Fang FM, Huang TL, Chiu TJ, et al. Neutrophil lymphocyte ratio is an independent prognosticator in patients with locally advanced head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. Journal of Cancer Research and Practice 2019;6:170-8.

Yang L, Huang Y, Zhou L, Dai Y, Hu G. High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta-analysis. Head Neck. 2019;41:1525-35.

Gorphe P, Chekkoury Idrissi Y, Tao Y, Schernberg A, Ou D, Temam S, et al. Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation. Papillomavirus Res. 2018;5:32-37.

Kuo C, Hsueh WT, Wu YH, Yang MW, Cheng YJ, Pao TH, et al. The Role of Pretreatment Serum Neutrophil-to-Lymphocyte Ratio in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Pilot Study. Sci Rep. 2019;9:1618.

Kim DY, Kim IS, Park SG, Kim H, Choi YJ, Seol YM. Prognostic value of posttreatment neutrophil-lymphocyte ratio in head and neck squamous cell carcinoma treated by chemoradiotherapy. Auris Nasus Larynx. 2017;44:199-204.

Jiang Y, Qu S, Pan X, Huang S, Zhu X. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma. Oncotarget. 2018;9:9992-10004.